Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM). |
Targets&IC50 | Akt1:360 nM |
In vitro | DB07107 from DrugBank showed the highest binding energy (XP: -14.045 kcal/mol). DB07107 is more potent in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl [1]. |
Molecular Weight | 370.45 |
Formula | C23H22N4O |
CAS No. | 552332-71-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DB07107 552332-71-5 Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt DB-07107 DB 07107 inhibitor inhibit